FDA approval of Vevye tops 2023 cornea articles
Click Here to Manage Email Alerts
The top Healio cornea-related articles in 2023 included the FDA approval of Vevye for dry eye disease and the efficacy of azithromycin in the treatment of meibomian gland dysfunction.
Check out the year’s top cornea/external disease items below.
Image: Adobe Stock
Vevye receives FDA approval for dry eye disease
The FDA approved Vevye, a 0.1% cyclosporine ophthalmic solution, for the treatment of signs and symptoms of dry eye disease, according to a press release from Novaliq. Read more.
Azithromycin shows equal efficacy to doxycycline in meibomian gland dysfunction treatment
Azithromycin showed equivalent efficacy to doxycycline in treating moderate to severe meibomian gland dysfunction, with reduced dosing and potentially fewer gastrointestinal adverse events, a study found. Read more.
Q&A: First-ever allogeneic cell therapy to treat corneal endothelial disease approved
Vyznova cell therapy received regulatory approval from Japan’s Pharmaceuticals and Medical Devices Agency for the treatment of bullous keratopathy, according to a press release from Aurion Biotech. Read more.
Speaker offers tips for navigating secondary dry eye disease
Dry eye is an umbrella term that covers multiple etiologies and different presentations. Read more.
VIDEO: Artificial tears may benefit patients with systemic diseases
In this Healio Video Perspective from Hawaiian Eye 2023, Lisa M. Nijm, MD, JD, discusses the importance of artificial tears in patients with systemic diseases who have chronic dry eye. Watch here.
Collapse
Healio Coverage
Read more about
Click Here to Manage Email Alerts